SI-BONE Narrows Losses on Strong 20% Revenue Growth

Ticker: SIBN · Form: 10-Q · Filed: 2025-11-10T00:00:00.000Z

Sentiment: mixed

Topics: Medical Devices, Sacroiliac Joint Fusion, Minimally Invasive Surgery, Revenue Growth, Net Loss, Cash Burn, Healthcare Technology, Orthopedics

TL;DR

**SIBN is burning cash but revenue growth is solid, making it a speculative buy for long-term growth in the medical device space.**

AI Summary

SI-BONE, Inc. (SIBN) reported a significant increase in revenue for the three and nine months ended September 30, 2025. Revenue for the three months increased by 20.6% to $48.656 million from $40.340 million in the prior year, while nine-month revenue grew 22.3% to $144.576 million from $118.176 million. Despite this strong top-line growth, the company continues to operate at a net loss, though it has narrowed. The net loss for the three months ended September 30, 2025, was $4.566 million, an improvement from a $6.575 million loss in the same period of 2024. Similarly, the nine-month net loss decreased to $17.260 million from $26.418 million year-over-year. Operating expenses increased, with sales and marketing rising to $29.956 million for the quarter and $91.418 million for the nine months, reflecting continued investment in market penetration. Cash and cash equivalents decreased to $26.487 million as of September 30, 2025, from $34.948 million at December 31, 2024, primarily due to net cash used in investing activities of $8.866 million and operating activities of $2.403 million over nine months. The company continues to expand its product lines, having launched iFuse INTRA and iFuse TORQ TNT in 2024, targeting sacroiliac joint dysfunction and pelvic trauma.

Why It Matters

SI-BONE's continued revenue growth, exceeding 20% year-over-year, signals strong market adoption for its minimally invasive sacroiliac joint fusion products, which is crucial for a medical device company. The narrowing net loss, from $6.575 million to $4.566 million quarterly, indicates improving operational efficiency and a potential path to profitability, which is a key metric for investors. This performance could strengthen SIBN's competitive position against other spinal and orthopedic device manufacturers by demonstrating the efficacy and demand for its specialized sacropelvic solutions. For patients, it suggests increasing access to advanced treatment options for chronic lower back pain. Employees benefit from a growing company with expanding product lines like iFuse INTRA and iFuse TORQ TNT, potentially leading to more job security and opportunities.

Risk Assessment

Risk Level: medium — SI-BONE reported a net loss of $4.566 million for the quarter and $17.260 million for the nine months ended September 30, 2025, indicating continued unprofitability. Cash and cash equivalents decreased by $8.461 million over the nine months, from $34.948 million to $26.487 million, primarily due to significant cash used in investing activities ($8.866 million) and operating activities ($2.403 million), suggesting ongoing cash burn despite revenue growth.

Analyst Insight

Investors should monitor SI-BONE's progress towards profitability and cash flow positivity. While revenue growth is strong, the continued net losses and cash burn warrant caution. Consider SIBN a growth play with inherent risks, suitable for investors with a higher risk tolerance looking for long-term potential in the medical device sector, especially given its specialized product offerings.

Financial Highlights

debt To Equity
0.36
revenue
$144.576M
operating Margin
-13.75%
total Assets
$234.273M
total Debt
$35.540M
net Income
($17.260M)
eps
($0.40)
gross Margin
80.09%
cash Position
$26.487M
revenue Growth
+22.3%

Revenue Breakdown

SegmentRevenueGrowth
Total Revenue$48.656M+20.6%
Total Revenue$144.576M+22.3%

Key Numbers

Key Players & Entities

FAQ

What were SI-BONE's revenues for the third quarter of 2025?

SI-BONE, Inc. reported revenues of $48.656 million for the three months ended September 30, 2025, representing a 20.6% increase compared to $40.340 million in the same period of 2024.

Did SI-BONE achieve profitability in Q3 2025?

No, SI-BONE, Inc. did not achieve profitability in Q3 2025. The company reported a net loss of $4.566 million for the three months ended September 30, 2025, although this was an improvement from the $6.575 million net loss in Q3 2024.

How much cash and cash equivalents did SI-BONE have as of September 30, 2025?

As of September 30, 2025, SI-BONE, Inc. had $26.487 million in cash and cash equivalents. This represents a decrease from $34.948 million at December 31, 2024.

What new products has SI-BONE launched recently?

SI-BONE, Inc. launched iFuse INTRA and iFuse TORQ TNT in 2024. These new product lines are designed for applications in sacroiliac joint dysfunction and pelvic trauma, expanding the company's offerings.

What is SI-BONE's primary business?

SI-BONE, Inc. is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for the treatment of musculoskeletal disorders of the sacropelvic anatomy.

What are the main risks highlighted in SI-BONE's 10-Q filing?

The filing highlights risks such as the ability to retain and grow its sales team, obtain and maintain favorable reimbursement determinations, competition, and factors impacting supply chains. The company also faces risks related to intellectual property disputes and regulatory approvals.

How has SI-BONE's operating loss changed year-over-year?

SI-BONE's loss from operations for the three months ended September 30, 2025, was $5.383 million, an improvement from a $7.633 million loss in the same period of 2024. For the nine months, the operating loss narrowed to $19.867 million from $29.754 million.

What was SI-BONE's sales and marketing expenditure in Q3 2025?

SI-BONE, Inc. spent $29.956 million on sales and marketing expenses for the three months ended September 30, 2025. This is an increase from $27.448 million in the comparable period of 2024, indicating continued investment in market expansion.

What is the weighted-average number of common shares used for EPS calculation for SI-BONE?

The weighted-average number of common shares used to compute basic and diluted net loss per share for the three months ended September 30, 2025, was 43,188,524. For the nine months, it was 42,775,206 shares.

Where is SI-BONE, Inc. headquartered?

SI-BONE, Inc. is headquartered in Santa Clara, California, at 471 El Camino Real, Suite 101.

Risk Factors

Industry Context

SI-BONE operates in the orthopedic device market, specifically focusing on minimally invasive surgical solutions for sacroiliac joint dysfunction and other spinal conditions. The industry is characterized by significant R&D investment, a need for clinical validation, and a competitive landscape with both established players and emerging technologies. Trends include a growing demand for less invasive procedures and solutions for chronic pain management.

Regulatory Implications

As a medical device company, SI-BONE is subject to stringent regulatory oversight by bodies like the FDA. Compliance with manufacturing standards, post-market surveillance, and approval processes for new devices are critical. Any adverse regulatory actions or delays in product approvals could significantly impact market access and financial performance.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Accumulated deficit
The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company has not yet achieved overall profitability, with a deficit of $448.614 million as of September 30, 2025.)
Operating lease right-of-use assets
An asset representing the right to use a leased asset over the lease term, recognized under ASC 842. (Reflects the company's use of leased facilities or equipment, with a balance of $1.255 million as of September 30, 2025.)
Additional paid-in capital
The amount investors have paid for stock above its par value. (Represents significant capital raised from equity issuance, totaling $619.964 million as of September 30, 2025.)
Comprehensive loss
Includes net loss plus other comprehensive income (or loss), such as foreign currency translation adjustments and unrealized gains/losses on investments. (Provides a broader view of the company's performance, showing a comprehensive loss of $16.732 million for the nine months ended September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year period, SI-BONE has demonstrated robust revenue growth, with a 20.6% increase in Q3 2025 and a 22.3% increase for the nine months ended September 30, 2025. While the net loss has narrowed significantly, the company continues to operate at a deficit. Operating expenses, particularly in sales and marketing, have increased to support this growth, and cash reserves have declined due to operational and investing activities.

Filing Stats: 4,598 words · 18 min read · ~15 pages · Grade level 17.4 · Accepted 2025-11-10 16:47:11

Key Financial Figures

Filing Documents

-FINANCIAL INFORMATION

PART I-FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets (Unaudited) 4 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 5 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) 6 Condensed Consolidated Statements of Cash Flows (Unaudited) 8 Notes to Condensed Consolidated Financial Statements (Unaudited) 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 35

-OTHER INFORMATION

PART II-OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 39 Item 6. Exhibits 40

SIGNATURES

SIGNATURES 42 1 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, prospective products and product candidates, sales force expansion, physician adoption, reimbursement determinations, clinical trial results, government shutdown, and U.S. Food and Drug Administration ("FDA") approvals, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions, including those described under the sections in this Quarterly Report titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." These forward-looking statements include, but are not limited to, statements about the following: our expectation that a significant portion of our revenue will be derived from sales of similar products addressing the sacropelvic anatomy; our ability to develop and commercialize additional revenue opportunities, including new indications for use and new products; our ability to

-FINANCIAL INFORMATION

PART I-FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements SI-BONE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 26,487 $ 34,948 Short-term investments 119,257 115,094 Accounts receivable, net of allowance for credit losses of $ 985 and $ 588 , respectively 26,534 27,459 Inventory 35,727 27,074 Prepaid expenses and other current assets 2,779 3,204 Total current assets 210,784 207,779 Property and equipment, net 21,928 20,374 Operating lease right-of-use assets 1,255 1,984 Other non-current assets 306 300 TOTAL ASSETS $ 234,273 $ 230,437 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 7,724 $ 6,488 Accrued liabilities and other 17,587 19,492 Operating lease liabilities, current portion 1,131 1,152 Total current liabilities 26,442 27,132 Long-term borrowings 35,540 35,452 Operating lease liabilities, net of current portion 165 879 Other long-term liabilities — 10 TOTAL LIABILITIES 62,147 63,473 Commitments and contingencies (Note 6) STOCKHOLDERS' EQUITY Preferred stock, $ 0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding — — Common stock, $ 0.0001 par value; 100,000,000 shares authorized; 43,273,382 and 42,086,477 shares issued and outstanding, respectively 4 4 Additional paid-in capital 619,964 598,070 Accumulated other comprehensive income 772 244 Accumulated deficit ( 448,614 ) ( 431,354 ) TOTAL STOCKHOLDERS' EQUITY 172,126 166,964 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 234,273 $ 230,437 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 SI-BONE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 20

View on Read The Filing